IPI Legacy Liquidation Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 118

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

IPI Legacy Liquidation General Information

Description

IPI Legacy Liquidation Co formerly Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.

Contact Information

Formerly Known As
Impel Pharmaceuticals
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 201 Elliott Avenue West
  • Suite 260
  • Seattle, WA 98119
  • United States
+1 (206)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Parent Company
Vertical(s)
Corporate Office
  • 201 Elliott Avenue West
  • Suite 260
  • Seattle, WA 98119
  • United States
+1 (206)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IPI Legacy Liquidation Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
27. Merger/Acquisition 12-Feb-2024 Completed Generating Revenue
26. Bankruptcy: Admin/Reorg 19-Dec-2023 Completed Bankruptcy: Admin/Reorg
25. General Corporate Purpose 21-Aug-2023 Completed Clinical Trials - Phase 3
24. General Corporate Purpose 17-Mar-2022 Completed Clinical Trials - Phase 3
23. 2PO 10-Sep-2021 Completed Clinical Trials - Phase 3
22. Debt Refinancing 06-Jul-2021 Completed Clinical Trials - Phase 3
21. IPO 22-Apr-2021 Completed Clinical Trials - Phase 3
20. Later Stage VC 12-Mar-2021 Completed Clinical Trials - Phase 3
19. Debt - General 05-Nov-2020 $30M $154M Completed Clinical Trials - Phase 3
18. Secondary Transaction - Private $124M Completed Clinical Trials - Phase 3
To view IPI Legacy Liquidation’s complete valuation and funding history, request access »

IPI Legacy Liquidation Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
IPI Legacy Liquidation Co formerly Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on uti
Drug Discovery
Seattle, WA
118 As of 2023

New York, NY
 

Emeryville, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IPI Legacy Liquidation Competitors (47)

One of IPI Legacy Liquidation’s 47 competitors is Curemark, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Curemark Venture Capital-Backed New York, NY
4D Molecular Therapeutics Formerly VC-backed Emeryville, CA
Ionis Pharmaceuticals Corporate Backed or Acquired Carlsbad, CA
Merck & Co. Corporation Rahway, NJ
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
You’re viewing 5 of 47 competitors. Get the full list »

IPI Legacy Liquidation Patents

IPI Legacy Liquidation Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021207626-A1 Repeated administration of dihydroergotamine for treatment of frequent migraine headaches Inactive 14-Jan-2020
AU-2021207626-A8 Repeated administration of dihydroergotamine for treatment of frequent migraine headaches Inactive 14-Jan-2020
CA-3167555-A1 Repeated administration of dihydroergotamine for treatment of frequent migraine headaches Pending 14-Jan-2020
EP-4090331-A1 Repeated administration of dihydroergotamine for treatment of frequent migraine headaches Inactive 14-Jan-2020
EP-4090331-A4 Repeated administration of dihydroergotamine for treatment of frequent migraine headaches Inactive 14-Jan-2020 A61K31/4985
To view IPI Legacy Liquidation’s complete patent history, request access »

IPI Legacy Liquidation Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IPI Legacy Liquidation Former Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
3M Ventures Corporate Venture Capital Minority
5AM Ventures Venture Capital Minority
Alliance of Angels Angel Group Minority
Atlas Accelerator Venture Capital Minority
Cowles Ventures Family Office Minority
You’re viewing 5 of 18 investors. Get the full list »

IPI Legacy Liquidation ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view IPI Legacy Liquidation’s complete esg history, request access »

IPI Legacy Liquidation FAQs

  • When was IPI Legacy Liquidation founded?

    IPI Legacy Liquidation was founded in 2008.

  • Where is IPI Legacy Liquidation headquartered?

    IPI Legacy Liquidation is headquartered in Seattle, WA.

  • What is the size of IPI Legacy Liquidation?

    IPI Legacy Liquidation has 118 total employees.

  • What industry is IPI Legacy Liquidation in?

    IPI Legacy Liquidation’s primary industry is Drug Discovery.

  • Is IPI Legacy Liquidation a private or public company?

    IPI Legacy Liquidation is a Private company.

  • What is IPI Legacy Liquidation’s current revenue?

    The current revenue for IPI Legacy Liquidation is .

  • How much funding has IPI Legacy Liquidation raised over time?

    IPI Legacy Liquidation has raised $348M.

  • Who are IPI Legacy Liquidation’s investors?

    3M Ventures, 5AM Ventures, Alliance of Angels, Atlas Accelerator, and Cowles Ventures are 5 of 18 investors who have invested in IPI Legacy Liquidation.

  • Who are IPI Legacy Liquidation’s competitors?

    Curemark, 4D Molecular Therapeutics, Ionis Pharmaceuticals, Merck & Co., and Alnylam Pharmaceuticals are some of the 47 competitors of IPI Legacy Liquidation.

  • When was IPI Legacy Liquidation acquired?

    IPI Legacy Liquidation was acquired on 12-Feb-2024.

  • Who acquired IPI Legacy Liquidation?

    IPI Legacy Liquidation was acquired by Woodward Pharma Services.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process